Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Rovunaptabin by Berlin Cures for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
Rovunaptabin is under clinical development by Berlin Cures and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC...